XML 37 R40.htm IDEA: XBRL DOCUMENT
v3.19.3

Assets and Liabilities Measured at Fair Value - Components by Hierarchy Level (Details) $ in Thousands | 3 Months Ended | 9 Months Ended |
--- | --- | --- | ---
Mar. 31, 2019 USD ($) | Sep. 30, 2019 USD ($) | Dec. 31, 2018 USD ($)
Assets: |  |  |
Fair value of assets |  | $ 351,802 | $ 427,084
Liabilities: |  |  |
Contingent consideration payable |  | 22,036 | 19,700
Deferred compensation plan liability |  | 4,003 | 2,732
Fair value of liabilities |  | 26,039 | 22,432
Milestone payment, stock issued as consideration |  | 9,000 |
Common Stock |  |  |
Liabilities: |  |  |
Milestone payment, stock issued as consideration | $ 9,300 |  |
ATB200 Pompe Program | Contingent Consideration Liability Clinical and Regulatory Milestones | Callidus Biopharma Inc |  |  |
Liabilities: |  |  |
Contingent consideration payable |  | $ 21,766 |
ATB200 Pompe Program | Contingent Consideration Liability Clinical and Regulatory Milestones | Probability of Milestone Achievement | Minimum | Callidus Biopharma Inc |  |  |
Liabilities: |  |  |
Discount rate |  | 0.75 |
ATB200 Pompe Program | Contingent Consideration Liability Clinical and Regulatory Milestones | Probability of Milestone Achievement | Maximum | Callidus Biopharma Inc |  |  |
Liabilities: |  |  |
Discount rate |  | 0.78 |
Commercial paper |  |  |
Assets: |  |  |
Fair value of assets |  | $ 114,808 | 115,141
Asset-backed securities |  |  |
Assets: |  |  |
Fair value of assets |  | 75,255 | 68,135
Corporate debt securities |  |  |
Assets: |  |  |
Fair value of assets |  | 139,745 | 240,726
U.S. government agency bonds |  |  |
Assets: |  |  |
Fair value of assets |  | 17,666 |
Money market funds |  |  |
Assets: |  |  |
Fair value of assets |  | 4,328 | 3,082
Level 2 |  |  |
Assets: |  |  |
Fair value of assets |  | 351,802 | 427,084
Liabilities: |  |  |
Contingent consideration payable |  | 0 | 0
Deferred compensation plan liability |  | 4,003 | 2,732
Fair value of liabilities |  | 4,003 | 2,732
Fair value of the Convertible Notes |  | 4,200 |
Level 2 | Commercial paper |  |  |
Assets: |  |  |
Fair value of assets |  | 114,808 | 115,141
Level 2 | Asset-backed securities |  |  |
Assets: |  |  |
Fair value of assets |  | 75,255 | 68,135
Level 2 | Corporate debt securities |  |  |
Assets: |  |  |
Fair value of assets |  | 139,745 | 240,726
Level 2 | U.S. government agency bonds |  |  |
Assets: |  |  |
Fair value of assets |  | 17,666 |
Level 2 | Money market funds |  |  |
Assets: |  |  |
Fair value of assets |  | 4,328 | 3,082
Level 3 |  |  |
Liabilities: |  |  |
Contingent consideration payable |  | 22,036 | 19,700
Deferred compensation plan liability |  | 0 | 0
Fair value of liabilities |  | $ 22,036 | $ 19,700
Level 3 | ATB200 Pompe Program | Contingent Consideration Liability Clinical and Regulatory Milestones | Probability Weighted Discounted Cash Flow | Discount Rate | Callidus Biopharma Inc |  |  |
Liabilities: |  |  |
Discount rate |  | 0.098 |

X
- Definition Contingent Consideration, Measurement Input + References No definition available. + Details
Name: | fold_ContingentConsiderationMeasurementInput
Namespace Prefix: | fold_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition Milestone Payment, Stock Issued As Consideration + References No definition available. + Details
Name: | fold_MilestonePaymentStockIssuedAsConsideration
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_AssetsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_AssetsFairValueDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. + References No definition available. + Details
Name: | us-gaap_ConvertibleDebtFairValueDisclosures
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements. + References No definition available. + Details
Name: | us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Fair value of financial and nonfinancial obligations. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_LiabilitiesFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_LiabilitiesFairValueDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=fold_ATB200PompeProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=fold_MeasurementInputProbabilityOfMilestoneAchievementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=fold_ProbabilityWeightedDiscountedCashFlowMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |